Ozmosi | Sarcolysin Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Sarcolysin

Alternative Names: sarcolysin
Clinical Status: Inactive
Latest Update: 2026-01-12
Latest Update Note: Clinical Trial Update

Product Description

St. Jude Children's Research Hospital is developing sarcolysin as an anticancer medicine. It is a type of chemotherapy that works by slowing or stopping growth of cancer cells. It may be used to help prepare patients for hematopoietic cell transplant. (Sourced from: https://together.stjude.org/en-us/diagnosis-treatment/medicines-list/melphalan.html)

Mechanisms of Action: Alkylating Agent

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: India | Russia

Approved Indications: None

Known Adverse Events: None

Company: City of Hope Medical Center
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Neuroblastoma|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Ganglioneuroblastoma

Phase 2: Graft vs Host Disease|Preleukemia|Sarcoma, Myeloid|Acute Myelomonocytic Leukemia|Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Chronic Lymphoid Leukemia|Acute Monocytic Leukemia|Anemia, Refractory, with Excess of Blasts|Lymphoma|Hodgkin Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Myeloid, Accelerated Leukemia|Leukemia|Lymphoma, B-Cell|Biphenotypic Acute Leukemia|Histiocytosis, Langerhans-Cell|Burkitt Lymphoma|Large-Cell Immunoblastic Lymphoma|HIV Infections|Melanoma|Multiple Myeloma|Mantle-Cell Lymphoma|Neuroblastoma|Paroxysmal Hemoglobinuria|Follicular Lymphoma|Anemia, Aplastic|Plasmablastic Lymphoma|T-Cell Lymphoma|Leukemia, Plasma Cell|Prolymphocytic B-Cell Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Waldenstrom Macroglobulinemia|Prolymphocytic Leukemia|Blast Crisis|Myelodysplastic-Myeloproliferative Diseases|Polycythemia Vera|Thrombocythemia, Essential|Myelofibrosis|Crohn Disease|Adult T-Cell Leukemia-Lymphoma|B-Cell Leukemia|Myeloproliferative Disorders|Prolymphocytic T-Cell Leukemia

Phase 1: Chronic Myeloid Leukemia|Preleukemia|Chronic Lymphoid Leukemia|Acute Myelomonocytic Leukemia|Myelodysplastic Syndrome|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Juvenile Myelomonocytic Leukemia,|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Myeloproliferative Disorders|Acute Monocytic Leukemia|Acute Myeloid Leukemia|Multiple Myeloma|Acute Lymphoid Leukemia|Anemia, Aplastic|Lymphoma, Non-Hodgkin|Blast Crisis|Leukemia, Plasma Cell|Neuroblastoma|Chronic Myelomonocytic Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Melanoma|Adenomyoepithelioma|Sarcoma, Ewing|Clear Cell Sarcoma|Renal Cell Carcinoma|Clear Cell Adenocarcinoma|Rhabdoid Tumor|Rhabdomyosarcoma|Gastrointestinal Cancer|Wilms Tumor|Lymphoma|Myeloid, Accelerated Leukemia|Biphenotypic Acute Leukemia

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

ACTRN12622000300774p

2006-7041-83/hah

N/A

Not yet recruiting

Chronic Cough

2023-10-31

NCT01769911

NCI-2012-03168

N/A

Withdrawn

AIDS-Related Lymphoma|Diffuse Large B-Cell Lymphoma|Large-Cell Immunoblastic Lymphoma|Extranodal NK-T-Cell Lymphoma|Hairy Cell Leukemia|Burkitt Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Mantle-Cell Lymphoma|Waldenstrom Macroglobulinemia|Sezary Syndrome|Immunoblastic Lymphadenopathy|T-Cell Peripheral Lymphoma|Adult T-Cell Leukemia-Lymphoma|Lymphoma, Non-Hodgkin|B-Cell Marginal Zone Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Large-Cell Anaplastic Lymphoma|Lymphomatoid Granulomatosis|Plasmablastic Lymphoma|T-Cell Cutaneous Lymphoma|Follicular Lymphoma|Leukemia, Plasma Cell|Intraocular Lymphoma|Large Granular Lymphocytic Leukemia|Mycosis Fungoides|Chronic Lymphoid Leukemia

2019-02-01

2024-11-27

Primary Endpoints

NCT02960646

NCI-2016-01915

P1

Completed

Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myeloid Leukemia|Lymphoma, Non-Hodgkin|Multiple Myeloma|Acute Lymphoid Leukemia|Blast Crisis|Chronic Lymphoid Leukemia|Acute Monocytic Leukemia|Leukemia, Plasma Cell|Chronic Myeloid Leukemia|Preleukemia|Anemia, Aplastic|Lymphocytic Chronic B-Cell Leukemia|Chronic Myelomonocytic Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Myelodysplastic Syndrome|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Lymphoma, B-Cell|Myeloproliferative Disorders|Juvenile Myelomonocytic Leukemia,|Acute Myelomonocytic Leukemia

2023-02-13

2023-02-18

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT01619761

NCI-2012-02071

P1

Unknown status

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Myeloid, Accelerated Leukemia|Myelodysplastic Syndrome|Leukemia, Plasma Cell|Lymphoma, B-Cell|Multiple Myeloma|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Preleukemia|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Biphenotypic Acute Leukemia|Lymphoma, Non-Hodgkin

2021-11-01

2022-02-02

Primary Endpoints|Treatments|Trial Status

NCT01625351

RADIANT

P1

Completed

Sarcoma, Ewing|Adenomyoepithelioma|Gastrointestinal Cancer|Rhabdomyosarcoma|Clear Cell Sarcoma|Lymphoma|Renal Cell Carcinoma|Wilms Tumor|Rhabdoid Tumor|Melanoma|Neuroblastoma|Clear Cell Adenocarcinoma

2020-02-10

2020-10-20

Primary Endpoints

NCT02130869

ASCIST

P1

Completed

Lymphoma|Neuroblastoma

2017-12-20

2024-11-27

Primary Endpoints

NCT02472392

Ewing/Allo

P1

Completed

Sarcoma, Ewing

2016-12-01

2019-03-20

Treatments

NCT05031897

21D.466

P2

Recruiting

Chronic Myeloid Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Multiple Myeloma|Myelofibrosis|Acute Monocytic Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Anemia, Aplastic|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Adult T-Cell Leukemia-Lymphoma|Lymphoma, Non-Hodgkin|Chronic Myelomonocytic Leukemia|Acute Myelomonocytic Leukemia|Myelodysplastic Syndrome|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Polycythemia Vera|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Thrombocythemia, Essential

2032-04-01

2025-10-31

Primary Endpoints

NCT05564390

MYELOMATCH

P2

Recruiting

Myelodysplastic Syndrome|Acute Myeloid Leukemia

2029-05-15

2026-01-13

NCT02727803

NCI-2016-00584

P2

Recruiting

Myeloproliferative Disorders|Preleukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myelodysplastic-Myeloproliferative Diseases|Chronic Lymphoid Leukemia|Lymphoma, B-Cell|Chronic Myeloid Leukemia|Leukemia, Plasma Cell|Acute Lymphoid Leukemia|Juvenile Myelomonocytic Leukemia,|Acute Myeloid Leukemia|Myeloid, Accelerated Leukemia|Chronic Myelomonocytic Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Acute Myelomonocytic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Anemia, Refractory, with Excess of Blasts|B-Cell Leukemia|Multiple Myeloma|Acute Monocytic Leukemia|Lymphoma, Non-Hodgkin|Biphenotypic Acute Leukemia|Myelodysplastic Syndrome

2027-05-31

2025-05-10

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT00692939

STUDY19100005

P2

Recruiting

Crohn Disease

2026-12-01

2025-12-16

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT02700841

0669-19-FB

P2

Terminated

Multiple Myeloma

2022-12-21

2023-08-30

Primary Endpoints|Start Date|Treatments

NCT03096782

NCI-2018-01236

P2

Completed

Preleukemia|Myeloid, Accelerated Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia|Lymphocytic Chronic B-Cell Leukemia|Juvenile Myelomonocytic Leukemia,|Anemia, Refractory, with Excess of Blasts|Myelodysplastic Syndrome|Lymphoma, Non-Hodgkin|Acute Monocytic Leukemia|Acute Lymphoid Leukemia|Chronic Myeloid Leukemia|Hodgkin Lymphoma|Lymphoma, B-Cell|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Biphenotypic Acute Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Histiocytosis, Langerhans-Cell

2022-09-20

2023-06-30

Primary Endpoints

NCT01904136

NCI-2013-02183

P2

Completed

Blast Crisis|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Myeloid, Accelerated Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia|Preleukemia

2022-02-28

2024-01-18

NCT01857934

Neuroblastoma Protocol 2012

P2

Active, not recruiting

Neuroblastoma

2021-10-21

2024-11-27

Primary Endpoints|Treatments

NCT01807611

HAPNK1

P2

Completed

Leukemia|Lymphoma

2021-08-27

2022-11-01

Patient Enrollment|Primary Endpoints|Treatments

NCT02797470

AMC-097

P2

Active, not recruiting

Large-Cell Immunoblastic Lymphoma|Lymphoma, Non-Hodgkin|Follicular Lymphoma|Mantle-Cell Lymphoma|T-Cell Lymphoma|Burkitt Lymphoma|Plasmablastic Lymphoma|HIV Infections

2021-05-13

2024-11-27

Primary Endpoints|Treatments

NCT04205240

OSU-19190

P2

Terminated

Multiple Myeloma

2021-05-08

2023-09-29

Primary Endpoints

NCT02756572

NCI-2016-00477

P2

Completed

Preleukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Anemia, Refractory, with Excess of Blasts

2020-03-01

2024-11-27

Primary Endpoints|Treatments

NCT01008462

NCI-2009-01334

P2

Completed

Chronic Lymphoid Leukemia|Prolymphocytic B-Cell Leukemia|T-Cell Lymphoma|Leukemia, Plasma Cell|Multiple Myeloma|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Prolymphocytic Leukemia|Lymphoma, Non-Hodgkin|Waldenstrom Macroglobulinemia|Prolymphocytic T-Cell Leukemia

2018-06-30

2024-11-27

Primary Endpoints

NCT01531244

11-X335

P2

Withdrawn

Melanoma

2016-02-01

2024-06-26

Primary Endpoints

NCT02259348

REFNK1

P2

Terminated

Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Juvenile Myelomonocytic Leukemia,|Myelodysplastic Syndrome|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Lymphoid Leukemia|Acute Monocytic Leukemia|Chronic Myelomonocytic Leukemia|Preleukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Sarcoma, Myeloid|Acute Myelomonocytic Leukemia|Chronic Myeloid Leukemia

2015-04-01

2019-03-20

NCT06172296

NCI-2023-08530

P3

Recruiting

Ganglioneuroblastoma

2029-12-31

2025-08-27

Primary Endpoints|Treatments

NCT05457556

ASCT2031

P3

Active, not recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|Myelodysplastic Syndrome|Preleukemia|Acute Myeloid Leukemia

2026-06-30

2025-05-06

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT00567567

ANBL0532

P3

Completed

Neuroblastoma

2015-02-27

2024-11-27

Primary Endpoints